{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=31", "query": { "intervention": "ARA C", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 906, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T06:13:11.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02029950", "title": "Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia-2", "High Risk Myelodysplastic Syndrome", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Idarubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2013-12-16", "completion_date": "2020-05-13", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Chapel Hill, North Carolina", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029950" }, { "nct_id": "NCT07604233", "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2026-11-30", "completion_date": "2033-06-03", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07604233" }, { "nct_id": "NCT01527149", "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Mantle Cell Lymphoma", "Stage II Contiguous Mantle Cell Lymphoma", "Stage II Non-Contiguous Mantle Cell Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 37, "start_date": "2011-12-06", "completion_date": "2024-01-11", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 2, "location_summary": "Buffalo, New York • Nashville, Tennessee", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527149" }, { "nct_id": "NCT07914166", "title": "Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Asciminib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Corticosteroid", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2027-10-13", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07914166" }, { "nct_id": "NCT00954941", "title": "Ondansetron Versus Aprepitant Plus Ondansetron for Emesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Diseases", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Ondansetron", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2009-11", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2015-06-25", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954941" }, { "nct_id": "NCT03896269", "title": "CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blasts 10-19 Percent of Bone Marrow Nucleated Cells", "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "High Risk Chronic Myelomonocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Chronic Myelomonocytic Leukemia", "Refractory High Risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2019-05-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896269" }, { "nct_id": "NCT02101983", "title": "Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytosine Arabinoside", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "55 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2011-05", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101983" }, { "nct_id": "NCT01843179", "title": "Sulindac for Patients With AML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843179" }, { "nct_id": "NCT02306291", "title": "Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "GMI-1271", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlycoMimetics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2015-03", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2019-05-17", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 6, "location_summary": "Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02306291" }, { "nct_id": "NCT00002818", "title": "High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "deoxycytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "1995-02", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-11-13T06:13:11.714Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002818" } ] }